Hidden Gem Deep Dive
A company that could 10x if thier clinical trial is successful - we will know in 12 weeks time
This company is a small but fast‑growing European healthcare player that has quietly built a leadership position in a niche market. They are 3 years ahead of any competition, bringing a similar treatment to market.
They are in the early stages of trialling treatments aimed at healing chronic wounds, and even treating severe respiratory infections through a novel patented delivery system currently in advanced trials.
If the trials are successful, this could be a 10-bagger in a short period; if not, it could be fatal for the company and could go to zero.
Despite its tiny market cap and low institutional ownership, it has secured exclusive technology rights, long‑term distribution agreements to scale and grow.
They have a razor‑blade like recurring revenue model, accelerating growth forecasts, and a high‑stakes regulatory catalyst on the horizon, this company represents a rare early‑stage opportunity with both outsized potential.
Here are a few more things that I like
€150M Market Cap
<1% instituational ownership
>50% insiders owners
+80% YTD price improvement
👉 Unlock this section to see the full analysis.